68. 効果は否定的
□ ORIGINAL ARTICLE □
Effect of Neutrophil Elastase Inhibitor (Sivelestat Sodium)
in the Treatment of Acute Lung Injury (ALI) and Acute
Respiratory Distress Syndrome (ARDS):
A Systematic Review and Meta-Analysis
Kentaro Iwata1,2
, Asako Doi3,4
, Goh Ohji1,2
, Hideaki Oka2
, Yuichiro Oba2
, Kohei Takimoto2
,
Wataru Igarashi2
, David H. Gremillion5
and Toshihiko Shimada3
Abstract
Introduction Sivelestat is neutrophil elastase inhibitor, which is widely used in Japan for the treatment of
acute lung injury. However, the clinical efficacy of the medication has not been convincingly demonstrated.
Methods We conducted a systematic review and meta-analysis of randomized controlled trials on sivelestat
for the treatment of acute lung injury and acute respiratory distress syndrome. Studies were identified using
Intern Med 49: 2423-2432, 2010 DOI:
treatment of ALI with systemic inflammatory response syn-
drome (SIRS), and it is widely used in this country. How-
z
a
69. Figure 4. Subgroup analysis of 28-30 day mortality of sivelestat v control for treatment of ALI/
ARDS. Only studies conducted in Japan were included in this analysis. RR: relative risks, CI: confi-
dent intervals. Studies ordered by weight. Random effect model.
Intern Med 49: 2423-2432, 2010 DOI: 10.2169/internalmedicine.49.4010
Figure 4. Subgroup analysis of 28-30 day mortality of sivelestat v control for treatment of ALI/
ARDS. Only studies conducted in Japan were included in this analysis. RR: relative risks, CI: confi-
dent intervals. Studies ordered by weight. Random effect model.
Intern Med 49: 2423-2432, 2010
132. ICUでの鎮静
ガイドラインSpecial Article
Clinical Practice Guidelines for the Management
of Pain, Agitation, and Delirium in Adult Patients
in the Intensive Care Unit
Juliana Barr, MD, FCCM1
; Gilles L. Fraser, PharmD, FCCM2
; Kathleen Puntillo, RN, PhD, FAAN, FCCM3
;
E. Wesley Ely, MD, MPH, FACP, FCCM4
; Céline Gélinas, RN, PhD5
; Joseph F. Dasta, MSc, FCCM, FCCP6
;
Judy E. Davidson, DNP, RN7
; John W. Devlin, PharmD, FCCM, FCCP8
; John P. Kress, MD9
;
Aaron M. Joffe, DO10
; Douglas B. Coursin, MD11
; Daniel L. Herr, MD, MS, FCCM12
;
Avery Tung, MD13
; Bryce R. H. Robinson, MD, FACS14
; Dorrie K. Fontaine, PhD, RN, FAAN15
;
Michael A. Ramsay, MD16
; Richard R. Riker, MD, FCCM17
; Curtis N. Sessler, MD, FCCP, FCCM18
;
Brenda Pun, MSN, RN, ACNP19
; Yoanna Skrobik, MD, FRCP20
; Roman Jaeschke, MD21
Crit Care Med 2013; 41:263‒306
133. ICUでの鎮静
ガイドラインSpecial Article
Clinical Practice Guidelines for the Management
of Pain, Agitation, and Delirium in Adult Patients
in the Intensive Care Unit
Juliana Barr, MD, FCCM1
; Gilles L. Fraser, PharmD, FCCM2
; Kathleen Puntillo, RN, PhD, FAAN, FCCM3
;
E. Wesley Ely, MD, MPH, FACP, FCCM4
; Céline Gélinas, RN, PhD5
; Joseph F. Dasta, MSc, FCCM, FCCP6
;
Judy E. Davidson, DNP, RN7
; John W. Devlin, PharmD, FCCM, FCCP8
; John P. Kress, MD9
;
Aaron M. Joffe, DO10
; Douglas B. Coursin, MD11
; Daniel L. Herr, MD, MS, FCCM12
;
Avery Tung, MD13
; Bryce R. H. Robinson, MD, FACS14
; Dorrie K. Fontaine, PhD, RN, FAAN15
;
Michael A. Ramsay, MD16
; Richard R. Riker, MD, FCCM17
; Curtis N. Sessler, MD, FCCP, FCCM18
;
Brenda Pun, MSN, RN, ACNP19
; Yoanna Skrobik, MD, FRCP20
; Roman Jaeschke, MD21
Crit Care Med 2013; 41:263‒306痛み、不穏、せん妄
168. 血糖値
The new england
journal of medicine
established in 1812 march 26, 2009 vol. 360 no. 13
Intensive versus Conventional Glucose Control
in Critically Ill Patients
The NICE-SUGAR Study Investigators*
ABSTR ACT
The NICE-SUGAR study is a co
tion of the Australian and New
Intensive Care Society Clinica
Group, the George Institute for
tional Health (University of Sydn
Canadian Critical Care Trials Gro
ound
imal target range for blood glucose in critically ill patients remains unclear.
ds
24 hours after admission to an intensive care unit (ICU), adults who were
d to require treatment in the ICU on 3 or more consecutive days were ran-
N Engl J Med 2009; 360: 1283-97
